Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and hypercholesterolemia
Not Applicable
- Conditions
- Dyslipidemia
- Registration Number
- JPRN-UMIN000016112
- Lead Sponsor
- Okayama University, Department of Cardiovascular Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Triglyceride over 400mg/dl 2) Patients receiving insulin 3) Pregnant 4) Subjects who is allergic to ezetimibe 5) Severe liver disease 6) Serum creatinine over 2 mg/dl 7) Patients with acute myocardial infarction, unstable angina, or stroke within 3 months 8) Secondary hypercholesterolemia, familial hypercholesterolemia 9) Patients receiving ezetimibe or fibrates 10) Unsuitable patients for this study by physicians decision
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in PCSK9 concentration
- Secondary Outcome Measures
Name Time Method